Page 206 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 7
Table S2. Continued
Patient number
Eligible
CD20
0= negative (<95%), 1=positive (>95%)
BCL2 0=negative (<50%), 1=positive (50%), 9=not available
MYC-IHC 0=negative (<40%), 1=positive (>40%), 9=not available
CD10 0=negative, 1=positive, 9=not available
BCL6 0=negative (<40%), 1=positive (>40%), 9=not available
77 yes 1 0 1 9 9 78 yes 1 1 1 0 1
79 yes 1 1 1 1 1
80 yes 1 1 1 0 1 81 yes 1 0 1 1 1 82 yes 1 1 1 1 1 83 yes 1 1 1 0 1 84 yes 1 0 0 1 1 85 yes 1 1 1 1 1
BA= break apart, NOS= not otherwise specified.
Table S3. Positive and negative predictive value of PET results.
Table S3A: Positive and negative predictive values of EOT PET-CT scan for progression within 1 year.
Progression within 1 year
CMR at EOT no yes no 5 22 yes 51 4
PPV 81% NPV 93%
Table S3B: Positive and negative predictive values of interim PET-CT scan for EOT result. Response was simplified to “CMR” versus “no-CMR”.
CMR EOT *
CMR at interim no yes
no 15 10 yes 12 45
PPV 60% NPV 79%
*2 patients missing PET (due to progression) and 1 patient missing EOT PET-CT (off-protocol due to toxicity) were counted as failures.
Immunohistochemistry
204